Dynamic Healthcare M&A Database

Acquiring Party	Invitrogen Corp. (IVGN), a maker of technologies for disease research and drug discovery.
Transferring Party	Applied Biosystems Group / Applera (ABI), a developer of instrument-based systems, consumables, software, and services used in disease research and genetic analysis; pharmaceutical drug discovery, human identity testing and safety testing.
Sector	Diagnostics
Date	June 12, 2008
Analysis Applied Biosystems is one of several competitors in the race to develop faster, cheaper DNA analysis devices for sequencing human genes. It recently announced it had sequenced an entire human genome for less than $60,000, down from the $3 billion spent on the Human Genome Project just 5 years ago. The deal will also allow the combined company to ramp up efforts to enter the emerging biomedical research markets in South Korea, China and India. The deal nearly doubles Invitrogen's consumables business. Deal value - $6.4b on sales and EBITDA of $2.17b and $491m, respectively.
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2007 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason.

Dynamic Healthcare M&A Database - 2Q08